Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.